Table 5.

Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling^*: Geographical Site of Recruitment Grouped as Regions

Baseline Characteristic	Multivariable
	Parameter Estimate	F	P Value	Partial R2
VKA experience
Warfarin experienced	Ref	129.71	<0.0001	0.0374
VKA experienced/warfarin naïve	−2.221
VKA naïve	−9.138
Region
Canada/United States	Ref	49.24	<0.0001	0.0426
Western Europe/similar	0.680
Latin America	−4.692
South Africa	−8.347
Eastern Europe	−8.598
East Asia	−8.680
India	−20.559
CHF	−3.172	37.05	<0.0001	0.0053
Female	−9.324	22.74	<0.0001	0.0033
COPD	−2.859	13.34	0.0003	0.0019
eGFR, 10 mL/min per 1.73 m2				0.0030
Linear	−6.474	11.36	0.0008
Quadratic	0.169	4.77	0.029
Hemoglobin, 2 g/L				0.0029
Linear	−8.794	11.17	0.0008
Quadratic	0.276	5.02	0.025
Systolic BP	−0.0453	9.39	0.0022	0.0014
BMI				0.0022
Linear	0.677	7.38	0.0066
Quadratic	−0.0086	5.13	0.024
Diabetes	−1.208	5.77	0.016	0.0008
Alcohol consumption, 12 mo
Abstinent	Ref	5.76	0.0006	0.0025
Light	1.772
Moderate	3.012
Heavy	−4.921
Medications at entry to the trial
Amiodarone	−3.608	16.42	<0.0001	0.0024
Statin	1.682	11.36	0.0008	0.0016
Aspirin	−1.111	4.10	0.043	0.0006

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; BP, blood pressure; BMI, body mass index.

^*For the multivariable model results reported in Table 4a through 4c, n=6961 with 22 subjects omitted because of missing covariate values.